• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伊博格碱的初步研究:病例报告及进一步研究建议。

A preliminary investigation of ibogaine: case reports and recommendations for further study.

作者信息

Sheppard S G

出版信息

J Subst Abuse Treat. 1994 Jul-Aug;11(4):379-85. doi: 10.1016/0740-5472(94)90049-3.

DOI:10.1016/0740-5472(94)90049-3
PMID:7966509
Abstract

A naturally occurring substance, ibogaine, was taken by seven individuals who were addicted to opiates. Ibogaine, an alkaloid with psychotropic effects at doses of 200-300 mg and above, was taken in single doses of 700-1800 mg by the subjects in the study. At the end of the 24-38-hr psychoactive period induced by the drug at these doses, none of the subjects displayed significant opiate withdrawal symptoms. At the lowest dose of 700 mg, one subject recontinued his drug abuse after 2 days; of the remaining six individuals who took 1,000 mg or above, two relapsed after a number of weeks, one reverted to intermittent heroin use, and three appear to have remained drug-free 14 weeks or more after undergoing this experimental treatment. Ibogaine may be of value in the present and could serve as a model for the development of improved agents for the treatment of substance abuse in the future.

摘要

七名阿片类药物成瘾者服用了一种天然存在的物质——伊博格碱。伊博格碱是一种生物碱,剂量在200 - 300毫克及以上时具有精神活性作用,研究中的受试者单次服用剂量为700 - 1800毫克。在这些剂量的药物诱导的24 - 38小时精神活性期结束时,没有一名受试者出现明显的阿片类药物戒断症状。在最低剂量700毫克时,一名受试者在两天后重新开始滥用药物;其余六名服用1000毫克及以上剂量的人中,两人在数周后复发,一人恢复间歇性使用海洛因,三人在接受这种实验性治疗后14周或更长时间似乎一直未再吸毒。伊博格碱目前可能具有价值,并且可以作为未来开发改进的药物滥用治疗药物的模型。

相似文献

1
A preliminary investigation of ibogaine: case reports and recommendations for further study.伊博格碱的初步研究:病例报告及进一步研究建议。
J Subst Abuse Treat. 1994 Jul-Aug;11(4):379-85. doi: 10.1016/0740-5472(94)90049-3.
2
Ibogaine in the treatment of heroin withdrawal.
Alkaloids Chem Biol. 2001;56:155-71. doi: 10.1016/s0099-9598(01)56012-5.
3
Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures.伊波加因:复杂的药代动力学、安全性问题及初步疗效评估
Ann N Y Acad Sci. 2000 Sep;914:394-401. doi: 10.1111/j.1749-6632.2000.tb05213.x.
4
Treatment of acute opioid withdrawal with ibogaine.用伊博格碱治疗急性阿片类药物戒断反应。
Am J Addict. 1999 Summer;8(3):234-42. doi: 10.1080/105504999305848.
5
Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes.用伊博格碱治疗阿片类物质使用障碍:戒毒及药物使用结果
Am J Drug Alcohol Abuse. 2018;44(1):24-36. doi: 10.1080/00952990.2017.1320802. Epub 2017 May 25.
6
Clinical efficacy of gamma-hydroxybutyric acid in treatment of opiate withdrawal.γ-羟基丁酸治疗阿片类物质戒断的临床疗效
Eur Arch Psychiatry Clin Neurosci. 1994;244(3):113-4. doi: 10.1007/BF02191883.
7
Ibogaine in acute opioid withdrawal. An open label case series.伊波加因治疗急性阿片类药物戒断。一项开放标签病例系列研究。
Ann N Y Acad Sci. 2000;909:257-9. doi: 10.1111/j.1749-6632.2000.tb06687.x.
8
The ibogaine medical subculture.伊博格碱医学亚文化。
J Ethnopharmacol. 2008 Jan 4;115(1):9-24. doi: 10.1016/j.jep.2007.08.034. Epub 2007 Aug 25.
9
Client and counselor attitudes toward the use of medications for treatment of opioid dependence.客户和咨询师对使用药物治疗阿片类药物依赖的态度。
J Subst Abuse Treat. 2007 Mar;32(2):207-15. doi: 10.1016/j.jsat.2006.09.002. Epub 2006 Dec 8.
10
Ibogaine in the treatment of substance dependence.伊波加因用于物质依赖的治疗。
Curr Drug Abuse Rev. 2013 Mar;6(1):3-16. doi: 10.2174/15672050113109990001.

引用本文的文献

1
Ibogaine administration following repeated morphine administration upregulates myelination markers 2', 3'-cyclic nucleotide 3'-phosphodiesterase (CNP) and myelin basic protein (MBP) mRNA and protein expression in the internal capsule of Sprague Dawley rats.在重复给予吗啡后给予伊波加因,可上调斯普拉格-道利大鼠内囊区髓鞘形成标志物2',3'-环核苷酸3'-磷酸二酯酶(CNP)和髓鞘碱性蛋白(MBP)的mRNA及蛋白表达。
Front Neurosci. 2024 Jul 24;18:1378841. doi: 10.3389/fnins.2024.1378841. eCollection 2024.
2
Ibogaine Induces Cardiotoxic Necrosis in Rats-The Role of Redox Processes.伊博加因诱导大鼠心脏毒性坏死——氧化还原过程的作用。
Int J Mol Sci. 2024 Jun 13;25(12):6527. doi: 10.3390/ijms25126527.
3
The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients.
阿片类物质使用障碍患者伊博加因的药代动力学和药效学。
J Psychopharmacol. 2024 May;38(5):481-488. doi: 10.1177/02698811241237873. Epub 2024 Mar 22.
4
Identifying setting factors associated with improved ibogaine safety: a systematic review of clinical studies.确定与提高伊博苷安全性相关的环境因素:临床研究的系统评价。
Eur Arch Psychiatry Clin Neurosci. 2023 Oct;273(7):1527-1542. doi: 10.1007/s00406-023-01590-1. Epub 2023 Mar 22.
5
Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: A Systematic Review of the Current Literature.伊博加因/去甲伊博加因治疗物质使用障碍:当前文献的系统评价。
Curr Neuropharmacol. 2023;21(11):2178-2194. doi: 10.2174/1570159X21666221017085612.
6
Ibogaine Has Sex-Specific Plasma Bioavailability, Histopathological and Redox/Antioxidant Effects in Rat Liver and Kidneys: A Study on Females.伊波加因在大鼠肝脏和肾脏中具有性别特异性的血浆生物利用度、组织病理学及氧化还原/抗氧化作用:一项针对雌性大鼠的研究
Life (Basel). 2021 Dec 23;12(1):16. doi: 10.3390/life12010016.
7
Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study.阿片类依赖者脱毒治疗中伊博加因给药的安全性:一项描述性、开放性、观察性研究。
Addiction. 2022 Jan;117(1):118-128. doi: 10.1111/add.15448. Epub 2021 Aug 9.
8
The iboga enigma: the chemistry and neuropharmacology of iboga alkaloids and related analogs.伊博加之谜:伊博加生物碱及相关类似物的化学和神经药理学。
Nat Prod Rep. 2021 Mar 4;38(2):307-329. doi: 10.1039/d0np00033g.
9
Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence.参与阿片类戒断综合征的非阿片类神经递质系统:临床前和人体证据综述。
J Pharmacol Exp Ther. 2019 Nov;371(2):422-452. doi: 10.1124/jpet.119.258004. Epub 2019 Aug 7.
10
Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes.伊波加因戒毒使阿片类药物和可卡因滥用者在依赖与戒断之间实现转变:临床观察与治疗结果
Front Pharmacol. 2018 Jun 5;9:529. doi: 10.3389/fphar.2018.00529. eCollection 2018.